Remove 2022 Remove Chemotherapy Remove Generic Medicine
article thumbnail

CHMP meeting highlights – December 2022

European Pharmaceutical Review

The group adopted a positive opinion for Tremelimumab AstraZeneca (tremelimumab), to treat metastatic non-small cell lung cancer (NSCLC) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy. EMA human medicines committee (CHMP) highlights, November 2022.

article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.

article thumbnail

Why cancer medicines are and continue to be vulnerable to drug shortages

Quality Matters

is facing a shortage of medicines that have been the backbone of cancer treatment plans for decades. increased nearly 30% from 2021 and 2022, marking the highest level of shortages in five years, according to data from the American Society of Health-System Pharmacists. While novel cancer therapies offer hope to patients, the U.S.